Patients with new acute leukemias of mixed or ambiguous lineage (MPAL/ALAL) should also be tested for FLT3 mutations at diagnosis, as FLT3 is mutated in a significant proportion of cases (from 12% overall, up to 47% in T/myeloid patients) [55,56,57]. This evidence concerns the gene FLT3 and acute leukemia.